TU-7710 is under clinical development by TiumBio and currently in Phase I for Hemophilia A (Factor VIII Deficiency). According to GlobalData, Phase I drugs for Hemophilia A (Factor VIII Deficiency) have a 97% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how TU-7710’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

TU-7710 overview

NBP-604 is under development for the treatment of hemophilia A and B. It is a recombinant long-acting activated Factor VII (FVIIa) fusion protein which is administetred through intravenous route..

TiumBio overview

TiumBio is a drug discovery company. The company’s pipeline products include chemical entity based drugs such as NCE401, NCE403, NCE406 and new biopharmaceuticals such as NBP604, NBP611 and NBP. The company develops therapies for the treatment of idiopathic pulmonary fibrosis, endometriosis, uterine fibroids, prostate cancer, type 2 diabetes mellitus, hemophilia and rare diseases. TiumBio is headquartered in Seongnam-si, Gyeonggi-do, Korea.

For a complete picture of TU-7710’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.